A new clinical trial focusing on adaptive prosthetic foot technology is set to commence under sponsorship by Otto Bock France SNC. With a primary objective to assess performance and usability in lower limb amputees, this trial utilizes the innovative Taleo Adjust prosthetic foot—a device designed to enhance user comfort by accommodating variable heel heights.
What changed?
The clinical trial, listed as “Not yet recruiting” on ClinicalTrials.gov as of October 9, 2025, marks a significant step in the evaluation of prosthetic foot technology designed for individuals with lower limb amputations. The Taleo Adjust prosthetic foot aims to address limitations in traditional prosthetics by providing enhanced versatility through adjustable heel height, ensuring compatibility with various footwear styles.
Who is affected?
This trial is designed for individuals with lower limb amputation, both above-knee and below-knee. Participants will compare the innovative Taleo Adjust prosthetic foot against their usual prosthetic device. Clinical teams and regulatory bodies involved in prosthetic device performance evaluation should closely follow developments in this space.
Device and intervention details
What is Taleo Adjust?
Taleo Adjust is an adaptive prosthetic foot manufactured by Otto Bock. The device features advanced adjustable heel height technology, allowing users to adapt footwear range without compromising stability, functionality, or comfort.
How is the study organized?
The trial will involve direct comparisons between the Taleo Adjust device and the participant’s regular prosthetic foot. Key metrics under investigation include usability, adaptability, and overall patient satisfaction during variable daily activities.
Why test adjustable heel height?
Traditional prosthetic feet limit footwear options for users due to fixed heel heights. Adjustable technology aims to resolve this issue, thereby enabling greater comfort and versatility without sacrificing performance.
FAQ
1. When will recruitment begin?
Recruitment dates have yet to be announced. As of October 9, 2025, the trial is listed as “Not yet recruiting.”
2. Who sponsors this trial?
The trial is sponsored by Otto Bock France SNC, a leading manufacturer of prosthetic and orthopedic devices.
3. How can I access further updates?
Updates will be provided on ClinicalTrials.gov under study ID NCT07214493.
Conclusion and next steps
This upcoming trial underscores the importance of innovation in adaptive prosthetic technologies. If successful, the Taleo Adjust device may redefine usability standards for prosthetic feet and provide valuable new options for patients. Clinical and regulatory teams should monitor this study for emerging data on performance and patient outcomes.
Disclaimer
This article is intended for informational purposes only and does not constitute professional or legal advice. Always consult relevant regulatory and clinical guidelines.
Link to clinical trial details
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07214493?term=medical+device